Cryo-medical injection device and method of use

ABSTRACT

The resorbable cryoprobe device and process is a novel approach for treating localized disease allowing for the precise combined application of freezing temperatures and cytotoxic or cryosensitizing agents within a self-contained matrix/package for optimized tissue destruction. The cryopellet is comprised of a list of components including a source of cryogen to produce the sub-zero temperatures, a porous matrix to contain the cytotoxic agent, cytotoxic agent, and a delivery packet. Data presented herein demonstrates the efficacy of this approach in destroying cancerous tissue. For example, the application of freezing temperatures to −10° C. results in approximately 15% cell death, while exposure to cytotoxic agents such as TRAIL produces minimal cell death. The utilization of the cryopellet approach results in a synergistic effect yielding complete cell death at the same temperature. The innovation behind the resorbable probe application includes the strategic combination of agents to activate intrinsic or extrinsic cell death responses (including apoptosis and necrosis), unique packaging of the cryogen and cytotoxic agent, and a unique delivery system. The resorbable cryoprobe technology will assist directly in the treatment of cancer, as well as will likely lead to broader application for disease treatment.

RELATED APPLICATIONS

The present application is a divisional application filed under 35U.S.C. §121 of pending U.S. Nonprovisional patent application Ser. No.12/607,721 and titled A Cryo-Medical Injection Device and Method of Usewhich is co-owned and claims priority to U.S. Provisional PatentApplication Ser. No. 61/240,863 filed on Sep. 9, 2009 and titledCryosensitizing Agents for the Enhancement of Cryoablation, which isincorporated herein by reference.

FIELD OF THE INVENTION

The present invention relates generally to the medical technology fieldand, in particular, to a medical device and method for use in cryogenictreatments.

BACKGROUND OF THE INVENTION

Over a recent number of years, there has been a strong movement withinthe surgical community toward minimally invasive therapies. The maingoals of the minimally invasive therapies include: 1) eradication oftargeted tissue, 2) decreased hospitalization time, 3) limitedpostoperative morbidities, 4) shortened return interval to dailyfunctions and work, and 5) reduced overall treatment cost.

Cryotherapy and cryosurgery (i.e. cryogenic treatments) are currentlyutilized for thousands of patients annually. The treatment provides aminimally invasive method of treating a disease state through tissuefreezing as opposed to surgical treatment or radiation therapy. Numerousdisease states include organ confined tumors such as prostate, kidney,liver, as well as cardiovascular disease, retinal detachment, painmanagement, and other illness/disease states such as cancer andcardiovascular disease.

Evidence demonstrates that standard therapies provide less than optimalefficacy in the treatment of prostate cancer (Moul, J., 1999; Van denOuden et al., 1998). Prostate cancer (CaP) is the second leading causeof cancer-related death in men in the United States with more than225,000 new cases diagnosed annually, approximately 40,000 resulting indeath (Carter and Isaacs, 2004; Oh, 2000; Petrylak, 1999). CaP is oftentreated initially with androgen ablation. Unfortunately, androgenablation is not curative in many patients and the disease recurs inlater years. Subsequent to anti-androgen failure, radical prostatectomyand radiation therapy (external beam or brachytherapy) provide treatmentoptions for localized prostate cancer. Additionally, there is often ahigh complication rate associated with these procedures characterized byhigh morbidity, long hospital/therapeutic intervals, incontinence, lossof potency, and additional adverse side effects. Given the high numberof annual cases of CaP and the high recurrent rate, the appropriateresources need to be gathered to develop and improve primary and salvagetreatment options.

Cryotherapy is an effective yet minimally invasive alternative tocurrent surgical procedures and radiation therapy approaches. Thesurgical procedure is done under either general or epidural anesthesiaand offers patients a quicker recovery and reduced severity of potentialside effects. For example, cryogenic treatment of prostate cancerreduces or potentially eliminates side effects such as incontinence.Without the expense associated with major surgery or an extendedhospital stay, cryosurgery is a cost-effective treatment option. Thetreatment is highly effective for low, moderate and high risk localizedprostate cancers. Impotence, however, remains an expected side effect oftargeted cryosurgery due to the freezing of tissue outside the gland tokill cancer cells that may have spread.

The approaches described thus far related to cryotherapy have focusedaround the development of devices which utilize stainless steelcryoprobes inserted into a target tissue, activation of a machine whichcirculates a cryogen (such as argon or liquid nitrogen) in the probe tocreate a heat sink thereby resulting in tissue freezing. Once freezingis complete, the probes are removed and the tissue left to die. None ofthe previous attempts have considered the nature of the cell/tissuedeath involved and the potential ways to manipulate the destruction ofdiseased tissue. In order to successfully reduce the positive freezemargin, methods or approaches are needed to elevate the critical killingtemperature or cryosurgical “dose”. The elevation of the critical killtemperature will not only apply to the freeze margin but also tospecific locations within the tumor itself (i.e. neurovascular bundles).Targeting and enhancing specific cell death pathways involved withcryoablation through the combination of known cytotoxic agents canresult in multiple cell stresses.

In addition, recent data demonstrate that when sub-lethal doses ofcytotoxic agents applied in vitro, such as TNF-RelatedApoptosis-Inducing Ligand (TRAIL), are applied in combination withfreezing, complete prostate cancer cell death occurs. This enhanced celldeath is in large part attained by the manipulation of the apoptotic,gene regulated, death cascade. Using this method, the critical deathtemperature has been reduced from −40° C. to −10° C.

The fundamental challenges faced by physicians using cryosurgery as atreatment for cancer revolve around the physics of the iceball produced,the surrounding anatomy, and the mechanisms of cellular destruction.Major anatomical structures, including the urethra, urinary bladder,rectal wall, and nerve bundles affecting erectile function, can becompromised during the procedure and result in secondary medicalchallenges to the patient (increased morbidity). To ensure completeablation of the diseased tissue, however, physicians need to freeze asignificant area beyond the disease margin. Many improvements have beenmade including monitoring of the freeze zone advancement and the use ofa urethral warming device. While the warming device has led to adecreased incidence of incontinence, this device may impede cellulardestruction within the tumor near the urethra.

The nature of cryosurgery generally requires a temperature of −40° C. orcolder to ensure complete cell and tissue destruction. In order toachieve this “dose” during a typical cryosurgical procedure, the icefront or positive freeze margin should extend from 2-5 mm beyond thetargeted tissue. This necessary positive freeze margin leads tosignificant damage to adjacent healthy tissue and unwanted patientside-effects. A variety of approaches have been developed in an attemptto minimize the freeze margin. Some of these include a change in thedesign of the probe resulting in different sized iceballs, an increasein the number of probes used for each procedure to produce a moreuniform iceball, and multiple freeze-thaw cycles. While each of thesetechniques has led to some improvement in the efficacy of the procedure,none of them have been successful at completely negating the need toextend the freeze zone. Some of the major drawbacks include the physicsof the ice formation and the isotherms generated, individuality amongstpatients, and differences between physician applications, all of whichlead to inconsistent results.

There exists a need for improvements in cryotherapy, and medical devicesor components associated with the treatment to better facilitate andimprove measures for treatment and cost. Studies are necessary todemonstrate that combining therapeutic strategies can increase theefficacy compared to each as a single agent. The combination of variouschemotherapeutic agents includes potential benefits of combiningclassical cryosurgery and chemotherapy. The use of adjuvant methods hasthe potential to significantly reduce the need to extend the freezemargin while attaining enhanced efficacy. Having the ability to targetspecific sites within or around the tumor will help to protect thoseareas not intended to be destroyed.

As cryosurgery continues to gain acceptance, future improvements to thedesign and application will be desired to significantly improve itsusage in prostate cancer as well as for the treatment of multiple othertypes of organ-confined tumors. While present treatments typically usecryosurgery as the sole therapy or as a single procedure, innovation andfuture developments will recognize the benefits of combination(neoadjunctive) therapies, including various therapeutic benefits in thecontrol and eradication of cancerous tumors.

The medical device and methods of the present invention will allow forthe simultaneous application of cryotherapy and cytotoxic agent therapyin a novel delivery system. The invention will desirably allow for theinsertion of single or multiple delivery systems to produce adestructive treatment and/or freeze zone. Further, the invention willprovide for a resorbable system or probe to more specifically target thedesignated tissue. The invention will facilitate the ablation oreradication of tissue, decrease procedural related side effects,increase therapeutic efficacy, decrease hospitalization time, limitpostoperative morbidities, shorten return to daily functions and work,and further reduce the overall treatment cost. Desirably, theseimprovements to device design and application will also increase itsutilization for the treatment of multiple disease states.

SUMMARY OF THE INVENTION

The resorbable probe approach offers the unique ability for thesimultaneous application of cryotherapy and cytotoxic agent therapy in anovel delivery system or contained packet. The resorbable probe orcryopellet approach allows for the insertion of multiple (single tohundreds) pellets to the target tissue to produce a destructivetreatment/freeze zone. The resorbable probe or resorbable cryopellettechnology also decreases procedural related side effects, increasestherapeutic efficacy, and reduces overall cost, ultimately leading toincreased cryosurgical application to numerous other disease states.

The following invention is a medical injection device comprising one ormore treatment pellets, an injection assembly which has a mechanism fordischarging the pellets, and a cartridge providing storage for thetreatment pellets and supplying pellets to the injection assembly. Aninsertion needle has a proximal end and a distal end such that thedistal end of the insertion needle designates at least one dispensingsite, or situs (defined region within tissue), for placement of one ormore of the treatment pellets into a targeted tissue.

In one embodiment, the medical injection device may be an insertionneedle with a cavity formed therethrough or the insertion needle mayserve more as a catheter or probe in an integral injection assembly suchthat a sleeve and plunger apparatus provide a mechanical force todispense a donut-shaped pellet from a storage cartridge into the targettissue.

In another embodiment, the injection assembly is a cryogun which fires ainjectable substrate or cryopellet into a target tissue. Alternatively,the cryogun may serve as an injection device to pre-treat the targettissue with an adjuvant prior to cryotreatment. In one aspect, thetreatment pellets comprise a porous matrix. In another aspect, thetreatment pellets are a cryo-formulation solidified and designed forresorption into the target tissue.

In one embodiment of the invention, an injectable substrate is used inthe treatment of the target tissue. The injectable substrate has a rigidor semi-rigid configuration for mechanical discharge into a targettissue site for use in the treatment of a target tissue, such that theinjectable substrate comprises a matrix which has a resorbablecomposition within a water soluble hydrophilic environment, and suchthat the matrix is an emulsion, gel, paste, liquid, or particulate form.Aspects of the injectable substrate may include a porous matrix havingvarying porosities. Various aspects of the substrate may incorporate anynumber of additives, binder materials, fillers, or tissue engineeredmatrices. The porosity of the matrices may also vary as dependent on thematerials and substrate compositions utilized.

In another embodiment, a method of using the device of the presentinvention is disclosed. The method of injecting one or more treatmentpellets or resorbable probes into a target tissue comprises the stepsof: providing a medical injection device having a storage unit, aninjection needle, and one or more treatment pellets; targeting a tissueto be treated; inserting the injection needle into the tissue at adefined site for treatment; and injecting one or more treatment pelletsinto a defined tissue site. In one aspect, the method includesdetermining an effective treatment plan for treating the tissue at oneor more defined sites within the tissue. In another aspect, thetreatment pellets are designed as resorbable cryoprobes and are capableof providing adjuvant therapy means to the tissue site.

In embodiments of the present invention, a cryopellet or cryoprobetechnology is utilized for the improved and successful ablation oflocalized (targeted) tissue in cancerous and benign tissues,noncancerous tissue, and irregular or nonconforming tissue structures.The cryopellet accomplishes this through utilization of the destructiveforce of freezing combined with specific cytotoxic agents in a deliverypacket which is applied to the diseased tissue using a uniquely designeddelivery system. Aspects of the inventive cryopellet are disclosed suchthat the cryopellet may be composed of a porous matrix, resorbable ornon-resorbable, in a frozen or non-frozen state, with or without acytotoxic agent (including but not limited to TRAIL, taxotere,cisplatin, etoposide, 5-FU, etc.), and delivering a time-released dosageof temperature and/or cytotoxic agent. The cryopellet can be deliveredas a stand alone pellet or in conjunction with a cryoprobe as currentlyused in the art to destroy target tissue. Furthermore, the conceptallows for the site-specific targeting of diseased tissue byfacilitating more precise delivery of a therapeutic dose to the desiredlocation. The cryopellet can be applied in either a frozen pelletformation or simultaneous injection of a non-frozen packet and inconjunction with a cryoprobe for site-specific tissue ablation.

BRIEF DESCRIPTION OF THE DRAWINGS

The invention is best understood from the following detailed descriptionwhen read with the accompanying drawing figures. It is emphasized thatthe various features are not necessarily drawn to scale. In fact, thedimensions may be arbitrarily increased or decreased for clarity ofdiscussion.

FIG. 1 is a side view of an illustrative embodiment of a device of thepresent invention.

FIG. 2 is an illustrative embodiment of a device of the presentinvention.

FIG. 3 is an illustrative embodiment of a device of the presentinvention.

FIG. 4 is a perspective view of the plunger described in the device ofFIG. 3.

FIG. 5 is a perspective view of a packet as described in the device ofFIG. 3.

DETAILED DESCRIPTION

In the following detailed description, for purposes of explanation andnot limitation, exemplary embodiments disclosing specific details areset forth in order to provide a thorough understanding of the presentinvention. However, it will be apparent to one having ordinary skill inthe art that the present invention may be practiced in other embodimentsthat depart from the specific details disclosed herein. In otherinstances, detailed descriptions of well-known devices and methods maybe omitted so as not to obscure the description of the presentinvention.

The resorbable probe device and approach to treat cancer, other bulkydiseased, irregular, or undesired tissue(s), represents an importantstep in targeted therapies. Numerous studies have been publisheddetailing various cryosurgical devices and procedures to apply freezingtemperatures to a target tissue. To date though, no reports detailing anapproach similar to a cryopellet or a resorbable probe approach toablate tissue have been disclosed. Furthermore, no device or deliverymethod has been developed to administer combined agents as do thetreatment pellets within the tissue or tumor site.

A device of the present invention is a medical injection device 10 asrepresented in FIG. 1. The injection device 10 has a cryogunconfiguration such that the body 2 of the cryogun 10 includes a handle 3and finger-grip trigger 4. The storage clip or cartridge 6 holds thetreatment pellets (see FIG. 2) to be dispensed. An insertion needle 8includes a proximal end 7 and a distal end 9.

In the embodiment of FIG. 1, the needle 8 has a cavity formed through itthat runs the length of the needle 8. An access panel 5 allows access tothe internal mechanism that facilitates discharge of the treatmentpellet(s) to the distal end of the needle at a tissue site. Upondischarge of the pellet, the pellet is directed from the storagecartridge 6 into and through the needle 8 to a target tissue. Theplacement of the distal end 9 of the insertion needle 8 designates thedispensing situs (or tissue site) where individual or multiple treatmentpellets are released into the tissue.

In one embodiment of FIG. 1, the needle can puncture tissue and beplaced as near to the target as possible. In one aspect, the needle canhave a diameter of any size and shape. The needle 8 may further containextensions to reach a more internal tissue or organ within the patientbeing treated. In another aspect, the needle is an integral unit ofmultiple lengths. On the other hand, the needle may contain distinctfragment lengths that are interconnected and disposable.

It should be noted that current methods utilize a mechanical dischargemethod though an air compression mechanism or other means for projectingthe pellet down the needle may be utilized.

As depicted in the embodiment of FIG. 1, the injection assembly 2 is thebody 2 of the cryogun and has a mechanism for discharging cryopellets toa target tissue. The storage clip 6 supplies the injection assembly withthe cryopellets and has a means for maintaining sub-zero temperatures. Acooling means or cooling mechanism may be integrated with the storageclip itself or with any portion of the cryogenic treatment device 10.The cooling mechanism keeps the cryopellets in a solidified state priorto release into the patient. Further, the insertion needle may be rigidor flexible to directionally place the cryopellets into the targettissue at its distal end. The needle itself can direct where thecryopellets are released.

In one aspect, the cryogenic treatment device 10 is connected to acryogen source. The cryogen source may be a fluid, including gases andliquids. For example, and not limitation, the cryogen source may includeargon, nitrogen, nitrous oxide, helium, freon, and other cryogenic gas,used individually, in combination, or in any mixtures thereof. Inanother aspect, cryogenic fluid can be directed to the storage clipwhere cryopellets are molded and formed prior to discharge. This wouldmaintain consistency of pellet size in the device utilized or allow forselected pellet size designs per each cartridge or per each cryogundesign.

Another embodiment may incorporate a cryopellet supply which has adirect feed into the storage clip. Then, the cryogenic treatment devicehas freedom of use anywhere in the patient setting without directattachment to a cryogen source.

FIG. 2 illustrates an injectable substrate 20 of the present invention.The injectable substrate 20 comprises a porous matrix 22 with aresorbable composition within a water soluble hydrophilic environment(although other porous matrices may be utilized such as for organicsolubility). The outer wall 21 of the substrate 20 is typically rigid orsemi-rigid for mechanical discharge into a target tissue site. Thematrix can be an emulsion, gel, paste, liquid, or particulate form insimilar configuration to that of an orally dissolvable capsule. Inanother aspect, the matrix may be an engineered synthetic or naturalformulation for supporting the compositions within an integral unit oras a unitary article.

The diameter of the pellet is typically between about 1 mm-10 mm,preferably between about 5 mm-10 mm, but may even be desired to be inthe range of about 1 mm-2 mm or smaller. The pellet size may be any sizethat facilitates ease of use of the medical injection device such thatthe pellet 20 is configured to fit within the storage clip and dischargethrough the distal end of the needle into the target tissue. Aspects ofthe injectable substrate, however, may include a porous matrix havingvarying porosities of any size and any dimension.

The length of the pellet may also extend between about 5 mm up to about20 mm in length. Again, the pellet is designed to facilitate ease of useof the medical device, but the pellet may also be engineered as to thetype of tissue being treated, including size and position of the tissuesite. Any dimension of pellet, however, is capable of formation butdevelopment of the pellet provides a design that also takes into accountthe tissue treatment plan, disease state of the tissue and other patientcare factors.

In addition, the pellet may be utilized in current brachytherapy systemsand methodologies. Making pellet diameters in the range of about 0.1mm-3 mm may be preferable. Lengths could vary in the same dimension orlarger. Actual dimensions and surface area can vary to achieve thedesired ablation volume or treatment area. Complete pellet sizessmaller, in the range of about 0.1 mm-0.9 mm may also satisfy minimallyinvasive therapeutic methodologies.

In FIG. 2, a cryopellet 20 is depicted having a diameter 24 of about 5mm with a length 25 of about 20 mm. The produced freeze zone diameter 27created is therefore up to about 15 mm. The produced freeze zone length28 is about 25 mm. As demonstrated, the cryopellet 20 has an extendedarea of treatment 23 predetermined by its design size, shape, andconfiguration. When the matrix of the treatment pellet is altered, theextended zones of treatment vary as dependent on the selected substratematerial 22.

Another embodiment of the invention is depicted in FIG. 3 as a medicalinjection device 30 having a packet or cartridge 32 which houses one ormore treatment pellets (see FIG. 5) or embodies a uniform treatmentpacket 32 for injection into a designated tissue site. The cartridge 32depicted here has a hollow core that is wrapped around the needle 34.The injection device 30 in this embodiment integrates the concept of acatheter/probe 34 which serves as the needle 34. As depicted, the needletip probe 34 is connected with a hose 36 which extends from a cryogenicconsole (not illustrated). An injection assembly/plunger 35 wraps itselfaround the needle 34, behind the cartridge 32 and pushes thecartridge/packet 32 over the catheter tip 33 and into the tissue wherethe tip of the needle is situated.

In one aspect, the injection device 30 is an injection guide 30 which isutilized in conjunction with a standard cryoprobe for the guidedplacement of the cryopellet into the targeted tissue. However, thenovelty of the invention as to the dispensable and resorbable cryoprobepellet can be varied to accommodate any cryo-instrumentation for thevarious surgical and/or cryotherapeutic procedures.

It is noted, however, that the needle-like probe may also be aneedle-tip catheter of any design or configuration. The pelletconfiguration may also be modified to conform to the medical injectiondevice design. A more detailed perspective view of the injectionassembly, or plunger 35, is depicted in FIG. 4. A hollow space 38 isinternal to the outer wall 39 and can be configured to integrallyconnect with the catheter/probe 34 of the injection device 30.

The treatment packet 32, as illustrated in FIG. 5, is a resorbable probe32. For exemplary purposes only and not limitation, the illustration ofFIG. 5 depicts a resorbable pellet 32 having a hollow core 37 to bedischarged over the surface of the catheter or probe tip 33. Thedimensions, size, shape and configuration of both plunger and treatmentpacket(s) can be modified to suit the type of tissue being treated.Further, the internal diameter of the hollow space 38 of the injectionassembly 35, as well as the internal diameter of the hollow core 37 ofthe resorbable pellet 32 may be similarly constructed for optimalperformance of the injection assembly. When one or more pellets 32 areutilized for treatment, the injection assembly 35 can controllablyrelease each pellet individually or in numerous quantitiessimultaneously. Insertion of the treatment pellets may be manual underthe user's direction or automated based on a desired treatment plan.Such treatment measures would permit consistency and accuracy intreatment procedure methods and less dependent on the user. A userinterface, however, allows easy control and manipulation of theinjection device, including precise mechanisms and electronic controlsfor ease of use.

More specifically, in the CryoPellet™ approach, a frozen pellet orpacket is inserted into the target tissue, freezes the adjacent tissue,and is left in place following application. The cryopellet can becomposed of either a resorbable or non-resorbable porous scaffold(liquid, semisolid, or solid) which is solidified or frozen to a desiredtemperature (typically ranging from −20° C. to −196° C.) prior toinjection. The cryopellet may also be impregnated with a single ormultiple cytotoxic agents including, but not limited to, TRAIL,docetaxel (Taxotere®), Cisplatin, etoposide, 5-Flurouricil (5-FU),paclitaxel (Taxol®), and other ligands and/or apoptotic drugs atclinical or sub-clinical doses. In addition, the composition of theporous matrix may be comprised of any biocompatible material, water,dimethyl sulfoxide (DMSO), ethanol, and including any cryosensitizingagent or cytotoxic agent dissolvable or suspendable in the selectedmedium. Other cryosensitizing agents as utilized may include vitamin D₃and other analogs. The selected medium creates a fluid-based (i.e.water-containing or liquid based) pellet in either liquid or solid form.For exemplary purposes and not limitation, any biologic orchemotherapeutic compound could be utilized or incorporated within theporous matrix to achieve a desired therapeutic outcome.

One example of a cryopellet configuration is a frozen carbon dioxidepellet (−79° C.) impregnated with the cytotoxic agent TRAIL. Anotherexample configuration is an aqueous solution of Taxotere® frozen to atemperature of −196° C. When injected, these cryopellets create mini iceballs within the target which destroys the surrounding tissue. In thecase of cryopellets containing cytotoxic agents, the combination of anagent and freezing act in conjunction with one another in a timedependent manner to destroy the target tissue. The frozen state of thecryopellet, with or without a cytotoxic agent delivers a time-releaseddosage of temperature and/or cytotoxic agent (if present).

In another configuration of the cryopellet, a non-frozen pellet(encapsulated liquid, semi-solid, or solid) is injected into the targettissue and is then frozen in situ utilizing the cooling power of acryoprobe. The agents with the pre-frozen configuration, non-frozenpellets, may consist of resorbable or non-resorbable porous scaffoldsand/or a single cryoagent or combination of cytotoxic agents.

These cryopellets can be best equated to the radioactive seeds utilizedin brachytherapy; however, in the case of the cryopellets, the lowtemperature nature of the pellet destroys the tissue where as inbrachytherapy, a piece of radioactive material is inserted into a tissuein attempt to kill the surrounding tissue over many weeks to months.

The innovation of this approach is that the cryopellet system offers anovel concept, approach, device and method for the treatment of cancer.The cryopellet system through its unique flexible design is the firstself-contained cryosurgical device and approach which can be utilized asa stand-alone therapy (in various configurations) or in conjunction withexisting cryosurgical devices. Utilization of the CryoPellet™ system hasthe potential to revolutionize the way cancer is treated through furtherreducing the invasive nature of cancer therapy procedures whileproviding for a highly effective approach to treating cancer.

In utilizing the medical device of the present invention, variousmethods in the industry may be employed in accordance with acceptedcryogenic applications. As discussed, the embodiments of the presentinvention are for exemplary purposes only and not limitation.Advantageously, this device represents an important step in targetedthermal therapies. Various cryosurgical devices and procedures to applyfreezing temperatures to a target tissue may be employed for use withthe medical device of the present invention. The medical device of thepresent invention has been developed to enable and improve some of theapproaches used to target or ablate tissue.

Thus, the invention facilitates other improvements in cryotherapy, andmedical devices or components associated with the treatment. Theinvention facilitates the eradication of tissue and can thereby decreasehospitalization time, limit postoperative morbidities, shorten return todaily functions and work, and further reduce the overall treatmentcosts. These improvements to device design and application can alsoincrease utilization of the device for the treatment of multiple diseasestates.

The embodiments of the present invention may be modified to take theshape of any device, container, apparatus, or vessel currently used inindustry. Further, any compartmental arrangement in combination with thecomponents of the above system may take many forms and be of any size,shape, or passageway. Any number of probes may also be utilized tofacilitate various treatment plans as determined by the patient. Inaddition, the device and instrumentation of the present invention mayintegrate a user interface of mechanical and/or electrical componentsfor facilitation of use in the medical setting. The user interface wouldpreferentially be easy to use and easy to control the internal injectionsystem and interoperability of the medical device and its injectablesubstrate.

As presented, the multiple embodiments of the present invention offerseveral improvements over standard medical devices currently used incryogenic industry. The previously unforeseen benefits have beenrealized and conveniently offer advantages for the treatment of multipledisease states. In addition, the improvements enable construction of thedevice as designed to enable easy handling, storage, and accessibility.Further uses of the system outside of the healthcare setting areforeseeable. Potential uses in the space industry, defense systems orany industry requiring rapid cooling may incorporate the cryogenicsystem as thus described.

As exemplified, the device may include any unitary structure or integralconfiguration with the capacity to integrally incorporate anycombination of such structures. The invention being thus described, itwould be obvious that the same may be varied in many ways by one ofordinary skill in the art having had the benefit of the presentdisclosure. Such variations are not regarded as a departure from thespirit and scope of the invention, and such modifications as would beobvious to one skilled in the art are intended to be included within thescope of the following claims and their legal equivalents.

What is claimed is:
 1. A cryotreatment pellet having a porous matrix ina rigid or semi-rigid configuration and frozen to a temperature betweenabout −60° C. to about −196° C., the porous matrix configured to delivera time-released ablative dosage of temperature within a target tissue,wherein the porous matrix remains intact as an integral unit wheninjected into the target tissue such that the time-released dosage oftemperature destroys the target tissue at an injection site and within adesignated zone of treatment.
 2. The cryotreatment pellet of claim 1,wherein the porous matrix has a resorbable composition within a watersoluble environment.
 3. The cryotreatment pellet of claim 1, wherein theresorbable composition is an emulsion, gel, paste, liquid, orparticulate form.
 4. The cryotreatment pellet of claim 1, wherein theporous matrix includes a tissue engineered scaffold that will resorbinto the target tissue.
 5. The cryotreatment pellet of claim 1, whereinthe porous matrix is a frozen carbon dioxide pellet.
 6. Thecryotreatment pellet of claim 1, wherein the porous matrix is an aqueoussolution of docetaxel or TRAIL frozen to a temperature of between about−79° C. to about −196° C.
 7. The cryotreatment pellet of claim 1,wherein the porous matrix comprises one or more cytotoxic agents.
 8. Thecryotreatment pellet of claim 1, wherein the porous matrix comprises abinder material.
 9. The cryotreatment pellet of claim 1, wherein theporous matrix comprises one or more cryo-adjuvants including athermophysical adjuvant, a chemotherapeutic molecule, a cytokine, avascular-based agent, an immunomodulator, or an apoptotic agent,individually or in any combination thereof.
 10. The cryotreatment pelletof claim 1, wherein the porous matrix includes TRAIL, docetaxel,cisplatin, etoposide, 5-FU, Vitamin D, or any cytotoxic agent, vitamin,or free radical scavenger.
 11. The cryotreatment pellet of claim 1,wherein the target tissue is a cancerous tissue, irregular tissue, orundesired tissue to be treated.
 12. The cryotreatment pellet of claim 1,wherein the porous matrix incorporates one or more hormone treatments.13. The method of injecting one or more cryotreatment pellets of claim1, comprising the steps of freezing the porous matrix and then injectingthe porous matrix into the target tissue by way of a contact needle;removing the contact needle from the target tissue; and allowing thetime-released ablative dosage of temperature to treat the target tissue.14. The method of claim 13, wherein the porous matrix comprises acytotoxic agent to deliver the time-released ablative dosage oftemperature in combination with the cytotoxic agent.